Alan Tan, MD, discusses upcoming trials that could change the landscape of frontline and adjuvant renal cell carcinoma ...
Patients with metastatic renal cell carcinoma staged pT1-4 Nx M1 were enrolled ... ultrasonic examinations and bone scintigraphy before and 12 week after the first immunization.
Share and Cite: Hinz, B. and Kenyon, J. (2025) Getting to a Diagnosis: A Rare Case of TFE3 Translocation Renal Cell Carcinoma ...
During a Case-Based Roundtable® event, Neeraj Agarwal, MD, and participants discussed how they might determine which ...
Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients ... can cause decreased renal function, the US Food and Drug ...
Hosted on MSN2mon
Upfront TKI for Bone-Predominant RCC Tops Single-Agent ImmunotherapyLOUISVILLE, Ky. -- Patients with bone-predominant metastatic renal cell carcinoma (RCC) appeared to have better outcomes when they started treatment with a targeted drug, results of a small ...
The most common type of kidney cancer is called a Renal cell Carcinoma which accounts for ... that most kidney cancers are ...
[20] The maximum recommended zoledronic acid dose for the treatment of bone metastases is 4 mg by IV ... testing to assess hydration status and renal function. Because all bisphosphonates are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback